CING
Cingulate Inc.
$4.69
-1.05%
$63.8M
No data for this timeframe.
Vol
Market Cap$63.8M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders3 funds
Inst. Value$693.4K
Inst. Activity1 buys / 0 sells
Insider Activity8B / 0S
Insider Net $$169.3K
Reddit Sentiment71° Bullish
SEC Reports4
Recent Activity
May 31, 2026
fda_pdufa
PDUFA: CING — CTx-1301 in ADHD — 2026-05-31
FDA target action date 2026-05-31 for CING (Cingulate Inc.). Drug: CTx-1301. Indication: ADHD. FDA a
Mar 31, 2026
Insider
Silva Raul R. sold 3,422 shares
EVP and CSO @ $0.00 ($0.00)
Mar 25, 2026
SEC
Cingulate Inc.'s Form S-3 shelf registration has become effective as of March 24, 2026, allowing the company to issue un
EFFECT — Impact 4/10
Mar 23, 2026
SEC
Cingulate Inc. filed an S-3/A amendment solely to update the auditor's consent from KPMG LLP. The filing does not modify
S-3/A — Impact 3/10
Mar 18, 2026
SEC
Cingulate Inc. filed a proxy statement supplement to correct an omission in its original filing, adding Falcon Creek Cap
DEFA14A — Impact 3/10
Mar 9, 2026
Insider
Callahan Jennifer L. sold 15,329 shares
EVP and CFO @ $0.00 ($0.00)
Mar 9, 2026
Insider
Patel Nilay Dahyabhai sold 2,086 shares
EVP, CLO and CCO @ $0.00 ($0.00)
Inst.
VANGUARD GROUP INC — DOUBLED
151,433 shares ($657.2K)
Price Targets
$25.90
+452.3% upside
Strong Buy
Current $4.69
Low $8.00
Median $25.00
High $55.00
5 analysts
$8.00
$55.00
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 8, 2026 | Ascendiant Capital | MAINTAIN | Buy → Buy |
| Mar 23, 2026 | Roth Capital | MAINTAIN | Buy → Buy |
| Dec 8, 2025 | Ascendiant Capital | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.70 ▼ -34.8% | $-0.77 — $-0.59 | 36% YoY | 3 |
| Next Q | $-0.67 ▼ -30.7% | $-0.75 — $-0.57 | 51% YoY | 3 |
| Current FY | $-2.63 ▼ -40.1% | $-2.84 — $-2.42 | 41% YoY | 2 |
| Next FY | $-1.92 ▼ -31.6% | $-2.79 — $-1.39 | 27% YoY | 4 |
Latest Reports
NEUTRAL
EFFECT
4/10
Cingulate Inc.'s Form S-3 shelf registration has become effective as of March 24, 2026, allowing the company to issue un
Mar 25, 2026
BEARISH
S-3/A
3/10
Cingulate Inc. filed an S-3/A amendment solely to update the auditor's consent from KPMG LLP. The filing does not modify
Mar 23, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $657.2K | DOUBLED |
| BANK OF AMERICA CORP | $31.9K | DOUBLED |
| MORGAN STANLEY | $4.3K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 31, 2026 | Silva Raul | A | $0.00 |
| Mar 9, 2026 | Callahan Jennifer | A | $0.00 |
| Mar 9, 2026 | Patel Nilay | F | $0.00 |
| Mar 9, 2026 | Callahan Jennifer | F | $0.00 |
| Mar 9, 2026 | Patel Nilay | A | $0.00 |
Reddit Sentiment
71°
Bullish
Bearish
Neutral
Bullish
3 institutional holders with $693.4K total value (159,774 shares) as of 2025-Q4. Top holders: VANGUARD, BANK, MORGAN. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 151,433 | $657.2K | 94.8% | DOUBLED +105.2% |
| 2 | BANK OF AMERICA CORP /DE/ | 7,341 | $31.9K | 4.6% | DOUBLED +283.1% |
| 3 | MORGAN STANLEY | 1,000 | $4.3K | 0.6% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | DOUBLED | 73,797 | 151,433 | +105.2% | $657.2K | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 35,377 | 73,797 | +108.6% | $289.3K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 12,645 | 1,298 | -89.7% | $5.1K | 2025-Q3 |
| VANGUARD GROUP INC | DOUBLED | 10,760 | 35,377 | +228.8% | $144.0K | 2025-Q2 |
| UBS Group AG | TRIM | 22,116 | 12,645 | -42.8% | $51.5K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 1,958 | 7,501 | +283.1% | $30.5K | 2025-Q2 |
| UBS Group AG | ADD | 12,196 | 22,116 | +81.3% | $95.1K | 2025-Q1 |
| VANGUARD GROUP INC | NEW | — | 10,760 | — | $46.3K | 2025-Q1 |
6 unique insiders with 8 transactions. Net insider value: $169.3K ($169.3K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | Silva Raul R. | EVP and CSO | A | 3,422 | $0.00 | $0.00 |
| Mar 9, 2026 | Callahan Jennifer L. | EVP and CFO | A | 15,329 | $0.00 | $0.00 |
| Mar 9, 2026 | Patel Nilay Dahyabhai | EVP, CLO and CCO | F | 2,086 | $0.00 | $0.00 |
| Mar 9, 2026 | Callahan Jennifer L. | EVP and CFO | F | 6,427 | $0.00 | $0.00 |
| Mar 9, 2026 | Patel Nilay Dahyabhai | EVP, CLO and CCO | A | 5,475 | $0.00 | $0.00 |
| Mar 9, 2026 | Schaffer Shane J. | Chief Executive Officer | F | 2,959 | $0.00 | $0.00 |
| Mar 9, 2026 | Silva Raul R. | EVP and CSO | F | 1,828 | $0.00 | $0.00 |
| Mar 9, 2026 | Silva Raul R. | EVP and CSO | A | 4,526 | $0.00 | $0.00 |
| Mar 9, 2026 | Schaffer Shane J. | Chief Executive Officer | A | 6,862 | $0.00 | $0.00 |
| Mar 9, 2026 | Brams Matthew | EVP and Chief Medical Officer | A | 4,526 | $0.00 | $0.00 |
| Mar 9, 2026 | Brams Matthew | EVP and Chief Medical Officer | F | 1,025 | $0.00 | $0.00 |
| Feb 6, 2026 | Brams Matthew | EVP and Chief Medical Officer | BUY | 1,556 | $0.1000 | $155.60 |
| Feb 6, 2026 | Brams Matthew | EVP and Chief Medical Officer | BUY | 1,946 | $5.04 | $9.8K |
| Feb 6, 2026 | Callahan Jennifer L. | SVP and CFO | BUY | 4,864 | $5.04 | $24.5K |
| Feb 6, 2026 | Callahan Jennifer L. | SVP and CFO | BUY | 3,891 | $0.1000 | $389.10 |
| Feb 6, 2026 | Werth Peter J. | Director | BUY | 19,455 | $5.04 | $98.1K |
| Feb 6, 2026 | Werth Peter J. | Director | BUY | 15,564 | $0.1000 | $1.6K |
| Feb 6, 2026 | Schaffer Shane J. | Chief Executive Officer | BUY | 6,809 | $5.04 | $34.3K |
| Feb 6, 2026 | Schaffer Shane J. | Chief Executive Officer | BUY | 5,447 | $0.1000 | $544.70 |
4 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 3 neutral. Avg impact: 3.5/10.
NEUTRAL
EFFECT
4/10
Cingulate Inc.'s Form S-3 shelf registration has become effective as of March 24, 2026, allowing the
Mar 25, 2026
BEARISH
S-3/A
3/10
Cingulate Inc. filed an S-3/A amendment solely to update the auditor's consent from KPMG LLP. The fi
Mar 23, 2026
NEUTRAL
DEFA14A
3/10
Cingulate Inc. filed a proxy statement supplement to correct an omission in its original filing, add
Mar 18, 2026
NEUTRAL
8-K
4/10
Analysis based on filing metadata only — document content was unavailable. The 8-K includes Items 2.
Mar 18, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$25.90 mean target
+452.3% upside
Strong Buy (1.33)
$8.00 Low
$55.00 High
| Metric | Value |
|---|---|
| Current Price | $4.69 |
| Target Low | $8.00 |
| Target Mean | $25.90 |
| Target Median | $25.00 |
| Target High | $55.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.33) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.70 | $-0.77 | $-0.59 | 36.1% | -34.8% | 1↑ 2↓ | $0.0B | 0.0% | 3 |
| Next Q 2026-09-30 |
$-0.67 | $-0.75 | $-0.57 | 50.6% | -30.7% | 1↑ 2↓ | $0.0B | 0.0% | 3 |
| Current FY 2026-12-31 |
$-2.63 | $-2.84 | $-2.42 | 40.8% | -40.1% | 1↑ 3↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-1.92 | $-2.79 | $-1.39 | 27.2% | -31.6% | 1↑ 0↓ | $0.0B | 0.0% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.697 | |
| 7d ago | $-0.517 | -0.180 |
| 30d ago | $-0.517 | -0.180 |
| 60d ago | $-0.513 | -0.183 |
| 90d ago | $-0.513 | -0.183 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 8, 2026 | Ascendiant Capital | MAINTAIN | Buy | Buy |
| Mar 23, 2026 | Roth Capital | MAINTAIN | Buy | Buy |
| Dec 8, 2025 | Ascendiant Capital | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
71°
Bullish
Bearish
Neutral
Bullish
3 mentions
3 bullish
0 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 26, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 21, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
NUAI, CING, SLS or FEMY…
▲ 1
💬 1
⚡ 0.5
CING (Cingulate)
▲ 13
💬 3
⚡ 0.1
May 31, 2026
fda_pdufa
PDUFA: CING — CTx-1301 in ADHD — 2026-05-31
FDA target action date 2026-05-31 for CING (Cingulate Inc.). Drug: CTx-1301. Indication: ADHD. FDA assigned PDUFA target action date of May 31, 2026 f
May 14, 2026
earnings
Cingulate Inc. Reports First Quarter 2026 Financial Results and Provides an Update of Commercial Readiness Efforts On Track for lead ADHD Asset CTx-1301
Cash Position Grows to $25.9 Million <pre>Cash Position Grows to $25.9 Million</pre>
May 14, 2026
short_volume
Short Volume: CING — 60.9% short (0.3M / 0.5M)
Short: 314,506 | Exempt: 35,263 | TRF Vol: 516,686 | Short Ratio: 60.9% | Off-exchange volume (dark pool + OTC)
Mar 18, 2026
earnings
Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
U.S. Patent Notice of Allowance for CTx-1301 Received; Additional European Patents Granted Recent $12M Private Placement Closed At-the-Market Pricing